Download Biomarkers in Alzheimer’s Disease Ebook PDF

Neuroimaging biomarkers in Alzheimer’s disease

Neuroimaging biomarkers in Alzheimer’s disease

by Samuel Barrack

  • Publisher : iMedPub
  • Release : 2013-10
  • Pages : 136
  • ISBN : 1492274429
  • Language : En, Es, Fr & De
GET BOOK

In view of the growing prevalence of AD worldwide, there is an urgent need for the development of better diagnostic tools and more effective therapeutic interventions. Indeed, much work in this field has been done during last decades. As such, a major goal of current clinical research in AD is to improve early detection of disease and presymptomatic detection of neuronal dysfunction, concurrently with the development of better tools to assess disease progression in this group of disorders. All these putative correlates are commonly referred to as AD-related biomarkers. The ideal biomarker should be easy to quantify and measure, reproducible, not subject to wide variation in the general population and unaffected by co- morbid factors. For evaluation of therapies, a biomarker needs to change linearly with disease progression and closely correlate with established clinico-pathological parameters of the disease. There is growing evidence that the use of biomarkers will increase our ability to better indentify the underlying biology of AD, especially in its early stages. These biomarkers will improve the detection of the patients suitable for research studies and drug trials, and they will contribute to a better management of the disease in the clinical practice. Indeed, much work in this field has been done during last decades. The vast number of important applications, combined with the untamed diversity of already identified biomarkers, show that there is a pressing need to structure the research made on AD biomarkers into a solid, comprehensive and easy to use tool to de deployed in clinical settings. To date there are few publications compiling results on this topic. That is why when I was asked to address this task I accepted inmediately. I am happy to present you a bundle of the best articles published about biomarkers for Alzheimer’s disease in recent times.

Biomarkers in Alzheimer's Disease

Biomarkers in Alzheimer's Disease
A Book

by Tapan Khan

  • Publisher : Academic Press
  • Release : 2016-08-02
  • Pages : 276
  • ISBN : 0128051477
  • Language : En, Es, Fr & De
GET BOOK

Biomarkers in Alzheimer’s Disease provides a comprehensive overview of all modalities of Alzheimer’s disease biomarkers, including neuroimaging, cerebrospinal fluid, genomic, and peripheral systems. Each chapter integrates molecular/cellular abnormality due to Alzheimer’s disease and technological advancement of biomarkers techniques. The book is ideal for clinical neuroscience and molecular/cellular neuroscience researchers, psychiatrists, and allied healthcare practitioners involved in the diagnosis and management of patients with cognitive impairment and Alzheimer’s disease, and for differential diagnosis of Alzheimer’s disease with other non-Alzheimer’s dementia. Presents a comprehensive overview detailing all modalities of Alzheimer’s disease biomarkers Written for neuroscience researchers and clinicians studying or treating patients with Alzheimer’s Disease Integrates, in each chapter, the molecular/cellular abnormality due to Alzheimer’s disease and the technological advancement of biomarkers techniques

Biomarkers of Alzheimer's Disease: The Present and the Future

Biomarkers of Alzheimer's Disease: The Present and the Future

by Sylvain Lehmann,Charlotte Elisabeth Teunissen

  • Publisher : Frontiers Media SA
  • Release : 2016-11-10
  • Pages : 329
  • ISBN : 2889450414
  • Language : En, Es, Fr & De
GET BOOK

Alzheimer disease (AD) is a neurodegenerative disorder characterized by significant cognitive deficits, behavioral changes, sleep disorders and loss of functional autonomy. AD represents the main cause of dementia and has become a major public health issue. In addition, the number of patients suffering from AD is growing rapidly as the population ages worldwide. Memory impairment is usually the earliest clinical and core symptom of this disease. The diagnosis at a late clinical stage is relatively easy. However, a delay in the diagnosis is damageable for the handling of patients in terms of optimal medical and social care. The actual interest of the scientific head-ways is to optimize the diagnosis in prodromal stage of the disease and to propose personalized therapeutic solutions to individual patients. New revised AD diagnostic criteria include early alteration of cerebrospinal fluid (CSF) biomarkers: decrease of amyloïd peptides (Aβ42), and increase in tau and phosphorylated-tau (p-tau) protein concentration. This recognition of CSF biological biomarkers for the diagnosis of AD is a major step towards the “molecular” diagnosis and follow-up of the disease. Many issues are however still subject of debate. This e-book provides a comprehensive overview of the state of the art of fluid biomarkers for AD, e.g. which novel biomarkers should be implemented in clinical practice for diagnosis or for monitoring treatment or side effects, which ones are new for AD or related dementias or what is the potential of peripheral blood markers. Moreover, the e-Book provides practical guidelines how to optimally and efficiently develop and validate novel biomarker assays, and to document and control pre-analytical variation.

Biomarkers for Early Diagnosis of Alzheimer's Disease

Biomarkers for Early Diagnosis of Alzheimer's Disease
A Book

by Daniela Galimberti,Elio Scarpani

  • Publisher : Nova Science Publishers
  • Release : 2008
  • Pages : 307
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Alzheimer's disease (AD) is characterized by the deposition into the brain of amyloid peptide, which originates a cascade of inflammatory events leading eventually to neuronal death. These pathological events likely occur several years before the clinical manifestation of the disease, implying that potential therapeutical interventions are currently started too late to give beneficial results. Recently, growing attention has been paid to the Mild Cognitive Impairment (MCI), considered the prodromal phase of AD, as 80% of subjects with MCI have been shown to develop AD within 5 years. Several studies aimed to identify biological markers to differentiate between normal aging and incipient AD have been carried out, including cerebrospinal fluid (CSF) analysis and neuroimaging. In particular, the evaluation of CSF Amyloid beta (1-42) levels, together with tau and phospotau, are of help for recognizing early AD. Besides, a number of additional molecules are altered in CSF. Other early modifications have been observed in peripheral cells, such as fibroblasts and leukocytes, as well as in serum from patients. Biomarkers for AD represent important tools supporting the clinical diagnosis and the choice of potential therapeutic options. Moreover, they would be of great help for the selection of cohorts of homogeneous patients for clinical trials with new disease-modifying compounds. This book is aimed to give an update about MCI as prodromal Alzheimer's disease (AD), to discuss the main known pathological mechanisms at the basis of AD and to describe the possible biomarkers to be used for an early diagnosis of the disease.

Neurodegenerative Diseases

Neurodegenerative Diseases
Clinical Aspects, Molecular Genetics and Biomarkers

by Daniela Galimberti,Elio Scarpini

  • Publisher : Springer Science & Business
  • Release : 2014-04-23
  • Pages : 253
  • ISBN : 144716380X
  • Language : En, Es, Fr & De
GET BOOK

This book gives an overview of the current knowledge on the most common neurodegenerative diseases, including Alzheimer’s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and additional neurodegenerative diseases. Different aspects of each disease are reviewed, including clinical issues, treatments, basic discoveries (genetics and molecular biology), and translation of basic research into biomarkers for early diagnosis. In addition, emerging data indicate that neurodegeneration seems to also be present in classically non-degenerative disorders. Therefore, a chapter about overlapping mechanisms between dementias and psychiatric disorders is included, as well as a description of the role of neurodegeneration in multiple sclerosis. Neurodegenerative Diseases is aimed at clinicians, particularly those working in academic hospitals. This multidisciplinary book will also be of interest to basic researchers in medical fields.

Oxford Textbook of Neurologic and Neuropsychiatric Epidemiology

Oxford Textbook of Neurologic and Neuropsychiatric Epidemiology
A Book

by Carol Brayne,Professor of Public Health Medicine and Director of the Cambridge University Department of Public Health Carol Brayne,Director National Institute for Stroke and Applied Neuroscience (Nisan) Valery Feigin,Valery Feigin,Lenore Launer,Giancarlo Logroscino

  • Publisher : Oxford University Press, USA
  • Release : 2020-11-02
  • Pages : 512
  • ISBN : 019874949X
  • Language : En, Es, Fr & De
GET BOOK

The Oxford Textbook of Neurologic and Neuropsychiatric Epidemiology focuses on the overlaps between neuro-epidemiological disorders. Harmonising cohort studies to determine causes related to rarer disorders, this key work is an invaluable reference to current neuro-epidemiological methods.

Alzheimer's Disease

Alzheimer's Disease
Understanding Biomarkers, Big Data, and Therapy

by Ahmed A. Moustafa

  • Publisher : Academic Press
  • Release : 2021-09-01
  • Pages : 400
  • ISBN : 0128213353
  • Language : En, Es, Fr & De
GET BOOK

Nearly 44 million people have Alzheimer’s or a related dementia worldwide, according to the Alzheimer’s Disease International organization. That number is expected to double every 20 years. Unlike other books on the market, Recent Advancement in Alzheimer’s Disease Research: Neural and Cognitive Studies aims to cover all recent advancements in cognitive, clinical, neural, and therapeutic aspects of Alzheimer’s and other forms of dementia. First, readers are introduced to the cognitive and clinical studies, focusing on the different types of memory impairment, past and future thinking. This includes the prevalence of depression, its relationship to symptoms and the quality of life in Alzheimer’s disease. In addition, the author discusses recent studies on memory dysfunction in advanced-stage Alzheimer’s disease, in comparison to early-stage Alzheimer’s disease; including a chapter on the factors underlying transition from mild cognitive impairment to Alzheimer’s disease. Following this section, the author presents recent studies on the role of different cortical and subcortical structures in the development of different symptoms in Alzheimer’s disease as well as different neural biomarkers underlying the development and treatment of Alzheimer’s disease. In the last section of the book, therapeutic aspects of Alzheimer’s disease, focusing on behavioral and pharmacological treatments of sleep disorders, memory problems, and depression, in Alzheimer’s disease are reviewed. Recent Advancement in Alzheimer’s Disease Research: Neural and Cognitive Studies aid readers with keeping up with the advances in research and care making it making it a prime tool for all clinicians, psychologists, researcher, neurologists, and caregivers of patients. Reviews recent developments of cognitive and clinical studies Covers factors underlying transition from mild cognitive impairment to Alzheimer's disease Discusses different neural biomarkers underlying the development and treatment of Alzheimer's disease Provides a comparison on the effectiveness of various types of treatments

Novel Biomarkers in Alzheimer’s Disease

Novel Biomarkers in Alzheimer’s Disease
A Book

by Chiara Villa

  • Publisher : MDPI
  • Release : 2021-02-05
  • Pages : 442
  • ISBN : 3039439030
  • Language : En, Es, Fr & De
GET BOOK

Alzheimer’s disease (AD) represents the most common form of dementia in the elderly population worldwide. AD is characterized by progressive neurodegeneration that leads to a gradual deterioration of memory and other cognitive functions. Given the global prevalence and impact of AD, there is a critical need to establish biomarkers that can be used to detect AD in individuals before the onset of clinical signs and provide mitigating therapeutics. The aim of this Special Issue is to discuss the current knowledge as well as future perspectives on the role of biomarkers in the screening, diagnosis, treatment and follow-up of AD.

Alzheimer's Disease

Alzheimer's Disease
Modernizing Concept, Biological Diagnosis and Therapy

by Harald Hampel,Maria C. Carrillo

  • Publisher : Karger Medical and Scientific Publishers
  • Release : 2012
  • Pages : 193
  • ISBN : 3805598025
  • Language : En, Es, Fr & De
GET BOOK

How current biomarkers are modernizing the diagnosis of Alzheimer's disease Expanding knowledge on genetic and epigenetic risk factors is rapidly enhancing our understanding of the complex molecular interactions and systems involved in the pathogenesis of Alzheimer's disease. In this publication, leading experts discuss emerging novel conceptual models of the disease along with advances in the development of surrogate markers that will not only improve the accuracy of diagnostic technologies but also improve the prospects of developing disease-modifying interventions. The novel framework of the disease presented here highlights research on biological markers as well as efforts to validate technologies for early and accurate detection. It also introduces notion of a complex systems dysfunction that extends beyond prevailing ideas derived from the amyloid' or tau' hypotheses. This outstanding publication provides researchers, clinicians, students and other professionals interested in neurodegenerative disorders with a comprehensive update on current trends and future directions in therapy development, with special focus on advances in clinical trial designs.

The Alzheimer's Disease Challenge

The Alzheimer's Disease Challenge
A Book

by Athanasios Alexiou,Mohammad A. Kamal,Ghulam Md Ashraf

  • Publisher : Frontiers Media SA
  • Release : 2019-12-04
  • Pages : 329
  • ISBN : 2889631281
  • Language : En, Es, Fr & De
GET BOOK

Alzheimer’s disease is undoubtedly the major health challenge of our Century with significant social and economic consequences. This Frontiers eBook offers a contribution of 39 innovative papers on the multidimensional and crucial problem of Alzheimer’s disease management and treatment. Several perspectives, research updates, and trials describing methods on potential diagnosis and treatment are presented including biological mechanisms, biomarkers and risk factors for an early and efficient prognosis, diagnosis and prevention. Additionally, while the rapidly increasing Alzheimer’s disease population demands holistic solutions and clinical studies with new therapeutic target approaches, several of the contributive papers present promising drugs targeting Alzheimer’s disease treatment. We give our deepest acknowledgment to all the authors for their important and innovative contributions, to the reviewers for their valuable recommendations on improving the submitting studies and all the Frontiers Editorial team for continuous support.

Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders

Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders
A Book

by Paul C. Guest

  • Publisher : Springer
  • Release : 2019-02-12
  • Pages : 328
  • ISBN : 3030055426
  • Language : En, Es, Fr & De
GET BOOK

This book includes a series of reviews on general aspects of biomarker use in the study of psychiatric and neurodegenerative diseases and the development of medications involved in their treatment. It describes the pros and cons of the various approaches and covers the successes and failures in this research field. It is only by a thorough understanding of the shortcomings that progress can be made. The overall goal is to facilitate the understanding and treatment of these disorders, by providing a viable mechanism of catching up with other areas of modern medicine, such as diabetes and heart disease. Finally, it is anticipated that the development and application of valid biomarker tests and the leveraging of novel drug targets will help the fields of psychiatry on neurodegenerative disorders move into the area of personalized medicine where the right patients can receive the right medication at the right time for the best possible outcome.

Genetic Variants in Alzheimer's Disease

Genetic Variants in Alzheimer's Disease
A Book

by Kevin Morgan,Minerva M. Carrasquillo

  • Publisher : Springer Science & Business Media
  • Release : 2013-06-22
  • Pages : 254
  • ISBN : 1461473098
  • Language : En, Es, Fr & De
GET BOOK

Alzheimer’s Disease is the most common form of dementia. The disease is characterised by the loss of synapses and neurons in the cerebral cortex and certain subcortical regions. In the last three years, the genetics of Alzheimer’s Disease has made significant advances; in fact, one could argue more than in the previous two decades. This has resulted in the identification of nine new genes and perhaps more importantly the realization that new pathways could be involved in the pathogenesis of Alzheimer’s. These new pathways are now legitimate targets for therapeutic intervention, which can possibly lead to treatment or a possible cure. The aim of this book is to put all of the recent genetic data on these new genes into context. Different genetic variants will be discussed, as well as biomarkers and future possibilities. ​

Biomarkers for Preclinical Alzheimer’s Disease

Biomarkers for Preclinical Alzheimer’s Disease
A Book

by Robert Perneczky

  • Publisher : Humana Press
  • Release : 2018-02-27
  • Pages : 272
  • ISBN : 9781493976737
  • Language : En, Es, Fr & De
GET BOOK

This volume discusses the importance of imaging, fluid, and genetic biomarkers in detecting the earliest pre-symptomatic stages of Alzheimer’s disease (AD). The chapters in this book are separated into five parts. Part one explores the reasons why we need improved approaches for early detection and diagnosis of AD. Part two describes clinical and research techniques for preclinical AD diagnosis. Part three looks at the current methods in use to diagnose AD and how they can also be used for early detection in healthy older individuals. Parts four and five talk about technological advancements in AD diagnosis and ethical considerations in AD research. In Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory. Comprehensive and cutting-edge, Biomarkers for Preclinical Alzheimer’s Disease is a valuable resource for individuals interested in the use of biomarker strategies to improve early AD detection. This book will be of great interest to researchers and clinicians from both academia and industry.”

Alzheimer's Disease

Alzheimer's Disease
Advances in Etiology, Pathogenesis and Therapeutics

by Khalid Iqbal,Sangram S. Sisodia,Bengt Winblad

  • Publisher : Wiley-Blackwell
  • Release : 2001
  • Pages : 852
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Alzheimer's Disease is an ever-present problem affecting millions of people around the world and, as people's average lifespan lengthens, its prevalence is set to increase. A global effort is needed to combat the disease, including research to investigate the causes, development of effective treatments and, ultimately, prevention of the disease. Published every two years, these timely books discuss the very latest research. This new volume in the series: Provides a uniques source of reference to the important work being done in this field Gives academics and clinicians an opportunity to learn about cutting edge developments Covers all aspects of Alzheimer's Disease, including diagnosis, clinical course, epidemiological course and therapeutics and disease mechanisms. Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics and Therapeutics will provide essential information for basic and clinical researchers in Alzheimer's Disease and other dementias as well as for those who care for patients.

Advances in Alzheimer's and Parkinson's Disease

Advances in Alzheimer's and Parkinson's Disease
Insights, Progress, and Perspectives

by Abraham Fisher,Maurizio Memo,Fabrizio Stocchi,Israel Hanin

  • Publisher : Springer Science & Business Media
  • Release : 2007-12-26
  • Pages : 490
  • ISBN : 9780387720760
  • Language : En, Es, Fr & De
GET BOOK

This volume contains the proceedings of the 2005 ADPD conference and is unique in that it deals not only with issues related individually to Alzheimer’s disease and Parkinson’s disease, but also with the integration of these and other related diseases. The most up-to-date techniques and research findings are illustrated in this volume, which covering topics from immunology, neuroscience, and pharmacology to genetics and molecular biology. Possible future developments in the treatment of Alzheimer’s and Parkinson’s Diseases are also covered.

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
Potential Biomarkers for Differential Diagnosis and the Effects of Intravenous Immunoglobulin Therapy

by Erin Jean Finehout

  • Publisher : Unknown Publisher
  • Release : 2006
  • Pages : 490
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Alzheimer's disease (AD) is a neurodegenerative disease affecting up to four million people in the United States. Using current diagnostic methods, it is estimated that up to 20% of antemortem AD diagnoses are incorrect. A biomarker for AD could complement current methods to increase the accuracy of diagnoses and make earlier diagnoses possible.

Biomarkers in Neurology

Biomarkers in Neurology
A Book

by Mohamed Mosaad Salama,Stefania Mondello,Firas H. Kobeissy,Wael M. Y. Mohamed

  • Publisher : Frontiers Media SA
  • Release : 2020-05-12
  • Pages : 329
  • ISBN : 2889636933
  • Language : En, Es, Fr & De
GET BOOK

Biomarker

Biomarker
Indicator of Abnormal Physiological Process

by Ghousia Begum

  • Publisher : BoD – Books on Demand
  • Release : 2018-09-05
  • Pages : 248
  • ISBN : 1789236665
  • Language : En, Es, Fr & De
GET BOOK

This book investigates the emerging use of biomarkers as a diagnostic tool for the identification of patients with an abnormal condition or as a tool for staging the extent of disease, as an indicator of disease prognosis. Chapters in Part I focus on biomarkers for cancer, including breast cancer and pancreatic cancer, as well as circulating microRNA profiling in cancer biomarker discovery. Chapters in Part II focus on biomarkers of other diagnoses/diseases, including sepsis, childhood renal diseases, pulmonary diseases, Alzheimer's, leishmaniasis, and heart failure. This book investigates the emerging use of biomarkers as a diagnostic tool for the identification of patients with an abnormal condition or as a tool for staging the extent of disease, as an indicator of diseases prognosis. The book is of considerable importance for a broad range of people including researchers, clinicians, and university students.

Alzheimer's Disease

Alzheimer's Disease
Advances for a New Century

by George Perry

  • Publisher : IOS Press
  • Release : 2013
  • Pages : 474
  • ISBN : 1614991537
  • Language : En, Es, Fr & De
GET BOOK

This volume is a companion to the highly successful book published in association with the Journal of Alzheimers Disease JAD on the centennial of Alzheimers discovery Alzheimers Disease A Century of Scientific and Clinical Research. Instead of looking back, this collection, Alzheimers Disease Advances for a New Century, will look forward. Using scientometric analysis the most promising developments since the Alzheimer Centennial in 2006 have been substantiated. While prior trends and advances in genetics, amyloid-, tau, neuropathology, and oxidative stress continue as active areas, emergent areas impacting the transition

Oxford Textbook of Old Age Psychiatry

Oxford Textbook of Old Age Psychiatry
A Book

by Tom Dening,Alan Thomas,John Paul Taylor,Robert Stewart

  • Publisher : Oxford University Press, USA
  • Release : 2020-11-05
  • Pages : 960
  • ISBN : 0198807295
  • Language : En, Es, Fr & De
GET BOOK

Part of the authoritative Oxford Textbooks in Psychiatry series, Oxford Textbook of Old Age Psychiatry, Third Edition has been thoroughly updated to reflect the developments in old age psychiatry since publication of the Second Edition in 2013, and remains an essential reference for anyone interested in the mental health care of older people.